Alan F. Denenberg

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by Intuit Inc. of $500 million aggregate principal amount of 0.650% notes due 2023, …

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Zscaler, Inc. of $1.15 billion aggregate principal amount of its 0.125%…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…

Davis Polk advised Equinix, Inc. on an SEC-registered offering of $2.6 billion aggregate principal amount of senior notes. The offering consisted of $500 million aggregate principal amount…

Davis Polk advised the underwriters in connection with a public offering of 6,666,667 shares of common stock of IDEAYA Biosciences, Inc. at $15.00 per share, for total gross proceeds of …

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by NetApp, Inc. of $750 million aggregate principal amount of its 1.875%…

Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an aggregate price to the public of approximately $89.4 million,…

Davis Polk advised Credo Technology Group Holding Ltd on its private placement of approximately $100 million in shares of its Series D preferred stock. Credo is a leading provider of high…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a follow-on offering of 4,025,000 shares of common stock of SiTime…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 5,980,000 shares of common stock of ChemoCentryx, Inc. (which…